Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: The role of receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 7, 2009, Pages 2269-2276

  Faienza, Maria Felicia ^a   Brunetti, Giacomina ^a   Colucci, Silvia ^a   Piacente, Laura ^a   Ciccarelli, Maria ^a   Giordani, Lucia ^a   Del Vecchio, Giovanni Carlo ^a   D'Amore, Massimo ^a   Albanese, Livia ^a   Cavallo, Luciano ^a   Grano, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CD11B ANTIGEN; CD51 ANTIGEN; CD61 ANTIGEN; COLONY STIMULATING FACTOR 1; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; STEROID 21 MONOOXYGENASE;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE DISEASE; CALCIUM BLOOD LEVEL; CELL MATURATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENETIC ANALYSIS; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LONG TERM CARE; MALE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SALT WASTING; STEROID 21 MONOOXYGENASE DEFICIENCY; T LYMPHOCYTE; WESTERN BLOTTING;

EID: 67650221408     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2446     Document Type: Article

References (40)

1. White PC, Speiser PW 2000 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21:245-291
2. Joint LWPES/ESPE CAH Working Group 2002 Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 87:4048-4053
3. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A 2006 Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17:144-149
4. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
5. Speiser PW, New MI 1993 Increased bone mineral density in congenital adrenal hyperplasia. Pediatr Res 33:S81
6. Cameron FJ, Kaimakci B, Byrt EA, Ebeling PR, Warne GL, Wark JD 1995 Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab 80:2238-2243
7. Jaaskelainen J, Voutilainen R 1996 Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 45:707-713
8. Girgis R, Winter JSD 1997 The effects of glucocorticoid replacement therapy on growth, bone mineral density and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 82:3926-3929
9. Hagenfeldt K, Ritzen EM, Ringertz H, Helleday J, Carlstrom K 2000 Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur J Endocrinol 143:667-671
10. Paganini C, Radetti G, Livieri C, Braga V, Migliavacca D, Adami S 2000 Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res 54:164-168
11. de Almeida Freire PO, de Lemos-Marini SH, Maciel-Guerra AT, Morcillo AM, Matias Baptista MT, de Mello MP, Guerra Jr G 2003 Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a cross selectional study of factors involved in bone mineral density. J Bone Miner Metab 21:396-401
12. King JA, Wisniewski AB, Bankowski BJ, Carson KA, Zacur HA, Migeon CJ 2006 Long term glucocorticoid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 91:865-869
13. Sciannamblo M, Russo G, Cuccato D, Chiumello G, Mora S 2006 Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase. J Clin Endocrinol Metab 91:4453-4458
14. Guo CY, Weetman AP, Eastell R 1996 Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 45:535-541
15. Mora S, Saggion F, Russo G, Weber G, Bellini A, Prinster C, Chiumello G 1996 Bone density in young patients with congenital adrenal hyperplasia. Bone 18:337-340
16. Gussinyè M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibanez L, Yeste D 1997 Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 100:671-674
17. Stikkelbroeck NMML, Oyen WJG, van der Wilt GJ, Hermus ARMM, Otten BJ 2003 Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 88:1036-1042
18. Christiansen P, Moolgard C, Muller J 2004 Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 61:133-136
19. Massey HM, Flanagan AM 1999 Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 106:167-170
20. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342
21. Theill LE, Boyle WJ, Penninger JM 2002 RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795-823
22. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309
23. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S, Liso V, Zallone A, Grano M 2004 T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104:3722-3730
24. Kanis JA, Glüer CC, for the Committee of Scientific Advisors, International Osteoporosis Foundation 2000 An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192-202
25. Reid IR 1997 Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 137:209-217
26. Conaway HH, Grogorie D, Lerner UH 1996 Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone. J Bone Miner Res 11:1419-1429
27. Dempster D 1998 Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 13:137-141
28. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanism of their deleterious effects on bone. J Clin Invest 102:274-282
29. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS 2005 Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20:390-398
30. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
31. Demulder A, Takahashi S, Singer FR, Hosking DJ, Roodman GD 1993 Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease. Endocrinology 133:1978-1982
32. Gregoretti MG, Bergui L, Aragno M, Cremona O, Marchisio PC, Caligaris-Cappio F 1995 Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma. Leukemia 9:1392-1397
33. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM 2003 Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821-831
34. Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, Ferracini R 2005 Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 19:228-230
35. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M 2002 Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells. Blood 99:634-640
36. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barille S, Bataille R, Rizzoli D 2002 Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100:4615-4621
37. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12
38. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Töz H, Atilla G, Hughes FJ, Belibasakis GN 2007 Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 34:370-376
39. Kobayashi A, Hirano F, Makino I 2005 The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scand J Rheumatol 34:480-484
40. Hofbauer LC, Zeitz U, Shoppet M, Scalicky M, Stolina M, Kostenuik PJ, Erben RG 2007 RANK ligand inhibition by Denosumab prevents cortical bone loss in a murine model of glucocorticoid-induced osteoporosis. Proc 29th Annual Meeting of the ASBMR J Bone Miner Res 22(S1):S4